Advanced Enzyme Technologies Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Advanced Enzyme Technologies de 10% y 12.3% por año respectivamente. Se prevé que el BPA crezca en un 10.2% al año. Se espera que la rentabilidad financiera sea de 12.2% en 3 años.
Información clave
10.0%
Tasa de crecimiento de los beneficios
10.16%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Chemicals | 19.5% |
| Tasa de crecimiento de los ingresos | 12.3% |
| Rentabilidad financiera futura | 12.20% |
| Cobertura de analistas | Low |
| Última actualización | 05 Feb 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Actualización de narrativa • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Actualización de narrativa • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Actualización de narrativa • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Actualización de narrativa • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Actualización de narrativa • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Actualización de narrativa • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Artículo de análisis • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Nueva narrativa • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Artículo de análisis • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Artículo de análisis • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Artículo de análisis • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Artículo de análisis • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Artículo de análisis • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Artículo de análisis • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Artículo de análisis • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Artículo de análisis • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Artículo de análisis • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Artículo de análisis • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Artículo de análisis • May 13
With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...Artículo de análisis • Mar 28
Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Artículo de análisis • Mar 13
The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find a...Artículo de análisis • Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
We note that a Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) insider, Madhusudan Soni, recently sold ₹5.7m...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2028 | 9,970 | 2,053 | 733 | 1,678 | 1 |
| 3/31/2027 | 8,535 | 1,729 | 876 | 1,441 | 1 |
| 3/31/2026 | 7,806 | 1,687 | 1,044 | 1,568 | N/A |
| 12/31/2025 | 7,096 | 1,522 | N/A | N/A | N/A |
| 9/30/2025 | 7,067 | 1,474 | 1,323 | 1,643 | N/A |
| 6/30/2025 | 6,683 | 1,369 | N/A | N/A | N/A |
| 3/31/2025 | 6,369 | 1,311 | 1,077 | 1,425 | N/A |
| 12/31/2024 | 6,275 | 1,329 | N/A | N/A | N/A |
| 9/30/2024 | 6,194 | 1,371 | 904 | 1,422 | N/A |
| 6/30/2024 | 6,311 | 1,386 | N/A | N/A | N/A |
| 3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
| 12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
| 9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
| 6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
| 3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
| 12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
| 9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
| 6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
| 3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
| 12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
| 9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
| 6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
| 3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
| 12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
| 9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
| 6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
| 3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
| 12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
| 9/30/2019 | 4,366 | 1,210 | N/A | 1,276 | N/A |
| 6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
| 3/31/2019 | 4,220 | 1,111 | N/A | 1,286 | N/A |
| 12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
| 9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
| 6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
| 3/31/2018 | 3,918 | 901 | N/A | 1,160 | N/A |
| 12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
| 9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
| 6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
| 3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
| 12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
| 9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
| 6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
| 3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10% al año) de ADVENZYMES es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (10% al año) de ADVENZYMES crezcan menos que el mercado Indian (16.3% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de ADVENZYMES crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (12.3% al año) de ADVENZYMES crezcan más rápidamente que los del mercado Indian (10.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 12.3% al año) de ADVENZYMES crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ADVENZYMES sea baja dentro de 3 años (12.2%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 10:28 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Advanced Enzyme Technologies Limited está cubierta por 4 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |